- Home
- FBIO vs IMUX Comparison
FBIO vs IMUX Comparison
Compare FBIO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- IMUX
- Stock Information
- Founded
- FBIO 2006
- IMUX 2016
- Country
- FBIO United States
- IMUX United States
- Employees
- FBIO N/A
- IMUX N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- FBIO Health Care
- IMUX Health Care
- Exchange
- FBIO Nasdaq
- IMUX Nasdaq
- Market Cap
- FBIO 88.7M
- IMUX 90.4M
- IPO Year
- FBIO N/A
- IMUX N/A
- Fundamental
- Price
- FBIO $3.38
- IMUX $0.85
- Analyst Decision
- FBIO Strong Buy
- IMUX Strong Buy
- Analyst Count
- FBIO 2
- IMUX 5
- Target Price
- FBIO $16.50
- IMUX $7.50
- AVG Volume (30 Days)
- FBIO 1.1M
- IMUX 1.3M
- Earning Date
- FBIO 08-14-2025
- IMUX 11-06-2025
- Dividend Yield
- FBIO N/A
- IMUX N/A
- EPS Growth
- FBIO N/A
- IMUX N/A
- EPS
- FBIO N/A
- IMUX N/A
- Revenue
- FBIO $59,301,000.00
- IMUX N/A
- Revenue This Year
- FBIO $51.59
- IMUX N/A
- Revenue Next Year
- FBIO $44.74
- IMUX N/A
- P/E Ratio
- FBIO N/A
- IMUX N/A
- Revenue Growth
- FBIO N/A
- IMUX N/A
- 52 Week Low
- FBIO $1.33
- IMUX $0.56
- 52 Week High
- FBIO $3.90
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- FBIO 71.65
- IMUX 47.73
- Support Level
- FBIO $2.79
- IMUX $0.74
- Resistance Level
- FBIO $3.90
- IMUX $0.96
- Average True Range (ATR)
- FBIO 0.25
- IMUX 0.05
- MACD
- FBIO 0.12
- IMUX -0.01
- Stochastic Oscillator
- FBIO 73.04
- IMUX 47.60
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.